Therapy Market Research Reports & Industry Analysis

Defined as treatment of disabilities/illnesses (physical and mental), therapy represents an essential branch of medicine. This term is widely used by psychologists to describe the session between them and patients. Depending on an illness, different therapies types are applied. Therapies may be aimed at the prevention of the disease occurrence, stopping its further progress or preventing an outbreak. They may be also used to improve a patient’s comfort.

Therapies are classified on the basis of energy (e.g. phototherapy and thermotherapy), human interaction (for instance, psychotherapy and psychotherapy) and matter (e.g. gene therapy and biotherapy), etc.

The Catalogue is an unprecedented source of research reports analyzing the therapy market in detail. The reports uncover the market sizing and segmentation, its present standing and future prospects. The research studies investigate the competitive environment and contain majors’ profiles. Market igniters and limiters are scrutinized, and trends and future opportunities are unveiled in the reports.

Found 3806 publications
Global Dry Heat Therapy Market Research Report 2016 US$ 2,850.00

2016 Global Dry Heat Therapy Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Dry Heat Therapy industry, focusing on the main ... with: 1.) basic information; 2.) the Asia Dry Heat Therapy industry; 3.) the North American Dry Heat Therapy industry; 4.) the European Dry Heat Therapy industry; 5.) market entry and investment feasibility; and ...

Sep, 2016 153 pages
Global Cold Therapy Market Research Report 2016 US$ 2,850.00

2016 Global Cold Therapy Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Cold Therapy industry, focusing on the main ... with: 1.) basic information; 2.) the Asia Cold Therapy industry; 3.) the North American Cold Therapy industry; 4.) the European Cold Therapy industry; 5.) market entry and investment feasibility; and ...

Sep, 2016 153 pages
Global Negative Pressure Wound Therapy Market by Manufacturers, Regions, Type and Application, Forecast to 2021 US$ 3,480.00

... wound dressing, and an adhesive film dressing that covers and seals the wound. Scope of the Report: This report focuses on the Negative Pressure Wound Therapy in Global market ... Homecare There are 13 Chapters to deeply display the global Negative Pressure Wound Therapy market. Chapter 1, to describe Negative Pressure Wound Therapy Introduction, product scope, market overview, market opportunities, market ...

Sep, 2016 113 pages
Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth US$ 4,995.00

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth Summary Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia ...

Aug, 2016 176 pages
Global Musculoskeletal Disorders Therapeutics Market 2016-2020 US$ 2,500.00

... scenario and the growth prospects of the global musculoskeletal disorder therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated ... , Global Musculoskeletal Disorder Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape ...

Aug, 2016 120 pages
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016 US$ 3,500.00

... Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development ...

Aug, 2016 70 pages
Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016 US$ 3,500.00

... Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016’, provides in depth analysis on Mycobacterium tuberculosis Protein Ag85A targeted pipeline therapeutics. The report provides comprehensive information on the Mycobacterium tuberculosis Protein Ag85A, targeted therapeutics ...

Aug, 2016 48 pages
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H2 2016 US$ 3,500.00

... therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development ...

Aug, 2016 52 pages
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016 US$ 2,000.00

... Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections ...

Aug, 2016 102 pages
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 US$ 3,500.00

... Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016’, provides in depth analysis on Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted pipeline therapeutics ...

Aug, 2016 59 pages
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016 US$ 2,000.00

... Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma ...

Aug, 2016 376 pages
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Pipeline Review, H2 2016 US$ 3,500.00

... Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) The report reviews Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics under development ...

Aug, 2016 38 pages
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016 US$ 3,500.00

... Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016 SUMMARY Global Markets Direct’s, ‘E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or ...

Aug, 2016 73 pages
Global Stroke Diagnostics and Therapeutics Market Report 2016 US$ 2,850.00

2016 Global Stroke Diagnostics and Therapeutics Market Report is a professional and in-depth research report on the world's major regional market conditions of the Stroke Diagnostics and Therapeutics industry ... : 1.) basic information; 2.) the Asia Stroke Diagnostics and Therapeutics industry; 3.) the North American Stroke Diagnostics and Therapeutics industry; 4.) the European Stroke Diagnostics and Therapeutics industry; 5.) market entry and ...

Aug, 2016 148 pages
Global Proton Therapy Market Report 2016 US$ 2,850.00

2016 Global Proton Therapy Report is a professional and in-depth research report on the world's major regional market conditions of the Proton Therapy industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Proton Therapy industry; 3.) the North American Proton Therapy industry; 4.) the European Proton Therapy industry; 5.) market entry and investment feasibility; and ...

Aug, 2016 148 pages
Global Pain Management Therapeutics Market Report 2016 US$ 2,850.00

2016 Global Pain Management Therapeutics Report is a professional and in-depth research report on the world's major regional market conditions of the Pain Management Therapeutics industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Pain Management Therapeutics industry; 3.) the North American Pain Management Therapeutics industry; 4.) the European Pain Management Therapeutics industry; 5.) market entry and investment feasibility; and ...

Aug, 2016 146 pages
Global Microbiome Therapeutics Market Report 2016 US$ 2,850.00

2016 Global Microbiome Therapeutics Report is a professional and in-depth research report on the world's major regional market conditions of the Microbiome Therapeutics industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Microbiome Therapeutics industry; 3.) the North American Microbiome Therapeutics industry; 4.) the European Microbiome Therapeutics industry; 5.) market entry and investment feasibility; and ...

Aug, 2016 146 pages
Global Liver Diseases Therapeutics Market Report 2016 US$ 2,850.00

2016 Global Liver Diseases Therapeutics Report is a professional and in-depth research report on the world's major regional market conditions of the Liver Diseases Therapeutics industry, focusing on the main regions ... with: 1.) basic information; 2.) the Asia Liver Diseases Therapeutics industry; 3.) the North American Liver Diseases Therapeutics industry; 4.) the European Liver Diseases Therapeutics industry; 5.) market entry and investment feasibility; and ...

Aug, 2016 146 pages
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase... US$ 3,500.00

... for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) The report reviews High Affinity Nerve Growth Factor Receptor ...

Jul, 2016 106 pages
Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016 US$ 3,500.00

Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016 SUMMARY Global Markets Direct’s, ‘Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 ...

Jul, 2016 106 pages
Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016 US$ 3,500.00

Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) - Pipeline Review, H2 2016 SUMMARY Global Markets Direct’s, ‘Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 ...

Jul, 2016 110 pages
Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016 US$ 3,500.00

... Ang 2 or ANGPT2) - Pipeline Review, H2 2016 SUMMARY Global Markets Direct’s, ‘Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016’, provides in depth analysis on Angiopoietin 2 (Ang 2 or ANGPT2) targeted pipeline therapeutics. The report provides comprehensive information on the Angiopoietin 2 (Ang ...

Jul, 2016 63 pages
EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2025 US$ 3,995.00

EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2025 Summary Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a ... procedure rates, as well as in the underlying demographic trends. Scope The Venous thromboembolism (VTE) EpiCast Report is an overview of the risk factors, comorbidities, and the global ...

Jul, 2016 69 pages
Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies US$ 4,995.00

Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies Summary Osteoporosis, the most common metabolic bone ...

Jul, 2016 131 pages
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs US$ 2,750.00

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs The report TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies ... ; Engineered TCR T-cells, including TCR target discovery; The current status of DLIs, CTLs and TILs; Manufacturing of T-cells for adoptive cell therapy; NK cells and CAR engineered NK cells; International perspective on TCR & CAR T-cell and NK cell ...

Aug, 2016 388 pages
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) The report reviews Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics under development ...

Jun, 2016 60 pages
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Pipeline Review, H1 2016 US$ 3,500.00

... Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a ...

Jun, 2016 39 pages
Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016 US$ 3,500.00

... Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016’, provides in depth analysis on Trans-Activator Of Transcription (Tat) targeted pipeline therapeutics. The report provides comprehensive information on the Trans-Activator Of Transcription (Tat), targeted therapeutics ...

Jun, 2016 43 pages
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016 US$ 3,500.00

... Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8), targeted therapeutics ...

Jul, 2016 74 pages
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) The report reviews Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) targeted therapeutics under development ...

Jun, 2016 68 pages
TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016 US$ 3,500.00

... TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016’, provides in depth analysis on TAR DNA-Binding Protein 43 (TDP-43) targeted pipeline therapeutics. The report provides comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43), targeted therapeutics ...

Jun, 2016 46 pages
Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H1 2016 US$ 3,500.00

... Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) The report reviews Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics under development ...

Jun, 2016 46 pages
Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H1 2016 US$ 3,500.00

... Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) The report reviews Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics under development ...

Jun, 2016 52 pages
Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7-Related Kinase or HsCdc7 or EC 2.7.11.1) targeted therapeutics under development ...

Jun, 2016 32 pages
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016 US$ 3,500.00

... Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016 SUMMARY Global Markets Direct’s, ‘Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted pipeline therapeutics ...

Jun, 2016 49 pages
Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) - Pipeline Review, H1 2016 US$ 3,500.00

... Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) The report reviews Caspase 9 (Apoptotic Protease Mch-6 or Apoptotic Protease-Activating Factor 3 or ICE-Like Apoptotic Protease 6 or EC 3.4.22.62) targeted therapeutics under development ...

Jun, 2016 70 pages
CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016 US$ 3,500.00

... CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016’, provides in depth analysis on CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted pipeline therapeutics. The report provides comprehensive information on the CaM Kinase (Ca2 ...

Jun, 2016 29 pages
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline... US$ 3,500.00

... for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine ...

Jun, 2016 100 pages
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor... US$ 3,500.00

Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Pipeline Review, H1 2016 ...

Jun, 2016 81 pages
Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016 US$ 3,500.00

... Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-Synuclein (alphaSyn or SNCA) targeted pipeline therapeutics. The report provides comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA), targeted therapeutics ...

Jun, 2016 84 pages
Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016 US$ 3,500.00

... Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-N-Acetylglucosaminidase (N-Acetyl-Alpha-Glucosaminidase or NAG or EC 3.2.1.50) targeted pipeline therapeutics ...

Jun, 2016 54 pages
Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Pipeline Review, H1 2016 US$ 3,500.00

... Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) The report reviews Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics under development ...

Jun, 2016 53 pages
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016 US$ 3,500.00

... Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12 ...

Jun, 2016 62 pages
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) The report reviews Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development ...

Jun, 2016 31 pages
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016 US$ 3,500.00

... Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted pipeline therapeutics. The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV ...

Jun, 2016 121 pages
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) The report reviews Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics under development ...

Jun, 2016 61 pages
Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) - Pipeline Review, H1 2016 US$ 3,500.00

... therapeutic landscape for Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) The report reviews Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) targeted therapeutics under development ...

Jun, 2016 72 pages
Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta or IKBKB or I-Kappa-B Kinase 2 or IKK2 or NFKBIKB or EC... US$ 3,500.00

... for Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear Factor NF-Kappa-B Inhibitor Kinase Beta or IKBKB or I-Kappa-B Kinase 2 or IKK2 or NFKBIKB or EC 2.7.11.10) The report reviews Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (I-Kappa B Kinase Beta or Nuclear ...

Jun, 2016 39 pages
Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016 US$ 3,500.00

... Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016’, provides in depth analysis on Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted pipeline ...

Jun, 2016 60 pages
Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 US$ 3,500.00

... Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016’, provides in depth analysis on Human Papilloma Virus (HPV) E7 Protein targeted pipeline therapeutics. The report provides comprehensive information on the Human Papilloma Virus (HPV) E7 Protein, targeted therapeutics ...

Jun, 2016 104 pages
1 2 3 4 5 >
Skip to top